Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Revenues Almost Double in Q2

NEW YORK – Quanterix reported after the close of the market on Thursday that its second quarter revenues were up 93 percent year over year.

The company posted Q2 revenues of $25.4 million, up from $13.1 million in Q2 2020 and above the consensus Wall Street estimate of $23.4 million.

Its Q2 product revenues rose almost threefold to $18.7 million from $6.8 million in Q2 2020. Service and other revenues were down 11 percent to $5.6 million from $6.3 million in the prior-year period.

"The past quarter has proven to be a pivotal time for our company as we continue to make immense strides with our strategic expansion in the diagnostics space," Kevin Hrusovsky, Quanterix's chairman, CEO, and president, said in a statement, noting in particular the company's role in diagnosing and monitoring neurodegenerative conditions like Alzheimer's disease.

The firm's Q2 net loss fell to $11.9 million from $12.3 million a year ago. It didn't provide a loss per share figure. Analysts, on average, had predicted a net loss of $.33 per share.

Quanterix's R&D spending during the quarter was up 57 percent to $6.8 million from $4.3 million in Q2 2020, and its SG&A expenses rose 59 percent to $20.8 million from $13.1 million the year before.

The company ended the quarter with $430.8 million in cash and cash equivalents.

In morning trading on the Nasdaq, Quanterix shares were down almost 6 percent at $53.80.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.